Theranostic Cancer Treatment Using Lentinan-Coated Selenium Nanoparticles and Label-Free CEST MRI

Selenium nanoparticle (SeNP)-based nanotherapeutics have become an emerging cancer therapy, while effective drug delivery remains a technical hurdle. A theranostic approach, through which imaging companions are integrated with SeNPs, will allow image-guided drug delivery and, therefore, is highly de...

Full description

Bibliographic Details
Main Authors: Guanfu Liu, Jiabao Ling, Lizhen He, Yuan Xu, Tianfeng Chen, Changzheng Shi, Liangping Luo
Format: Article
Language:English
Published: MDPI AG 2022-12-01
Series:Pharmaceutics
Subjects:
Online Access:https://www.mdpi.com/1999-4923/15/1/120
_version_ 1797437821275865088
author Guanfu Liu
Jiabao Ling
Lizhen He
Yuan Xu
Tianfeng Chen
Changzheng Shi
Liangping Luo
author_facet Guanfu Liu
Jiabao Ling
Lizhen He
Yuan Xu
Tianfeng Chen
Changzheng Shi
Liangping Luo
author_sort Guanfu Liu
collection DOAJ
description Selenium nanoparticle (SeNP)-based nanotherapeutics have become an emerging cancer therapy, while effective drug delivery remains a technical hurdle. A theranostic approach, through which imaging companions are integrated with SeNPs, will allow image-guided drug delivery and, therefore, is highly desirable. Traditional methods require the chemical conjugation of imaging agents to the surface of nanoparticles, which may impede the later clinical translation. In this study, we developed a label-free strategy in which lentinan-functionalized SeNPs (LNT-SeNPs) are detected using MRI by the hydroxyl protons carried on LNT molecules. The in vitro phantom study showed that LNT and LNT-SeNPs have a strong CEST signal at 1.0 ppm apart from the water resonance, suggesting an in vivo detectability in the µM concentration range. Demonstrated on CT26 colon tumor cells, LNT-SeNPs exert a strong anticancer effect (IC50 = 4.8 μM), prominently attributed to the ability to generate intracellular reactive oxygen species. However, when testing in a mouse model of CT26 tumors, administration of LNT-SeNPs alone was found unable to deliver sufficient drugs to the tumor, leading to poor treatment responses. To improve the drug delivery, we co-injected LNT-SeNPs and TNF-α, a previously reported drug that could effectively damage the endothelial cells in the tumor vasculature, thereby increasing drug delivery to the tumor. Our results revealed a 75% increase in the intratumoral CEST MRI signal, indicating a markedly increased delivery efficiency of LNT-SeNPs when combined with TNF-α. The combination therapy also resulted in a significantly enhanced treatment outcome, as revealed by the tumor growth study. Taken together, our study demonstrates the first label-free, SeNP-based theranostic system, in which LNT was used for both functional surface coating and CEST MRI signal generating. Such a theranostic LNT-SeNP system is advantageous because it requires chemical labeling and, therefore, has high biocompatibility and low translatable barriers.
first_indexed 2024-03-09T11:27:11Z
format Article
id doaj.art-0f8e02dec40a484cb670c8de3346ff71
institution Directory Open Access Journal
issn 1999-4923
language English
last_indexed 2024-03-09T11:27:11Z
publishDate 2022-12-01
publisher MDPI AG
record_format Article
series Pharmaceutics
spelling doaj.art-0f8e02dec40a484cb670c8de3346ff712023-11-30T23:57:57ZengMDPI AGPharmaceutics1999-49232022-12-0115112010.3390/pharmaceutics15010120Theranostic Cancer Treatment Using Lentinan-Coated Selenium Nanoparticles and Label-Free CEST MRIGuanfu Liu0Jiabao Ling1Lizhen He2Yuan Xu3Tianfeng Chen4Changzheng Shi5Liangping Luo6Department of Radiology, The First Affiliated Hospital of Jinan University, Guangzhou 510632, ChinaDepartment of Chemistry, Jinan University, Guangzhou 510632, ChinaDepartment of Chemistry, Jinan University, Guangzhou 510632, ChinaDepartment of Radiology, The First Affiliated Hospital of Jinan University, Guangzhou 510632, ChinaDepartment of Radiology, The First Affiliated Hospital of Jinan University, Guangzhou 510632, ChinaDepartment of Radiology, The First Affiliated Hospital of Jinan University, Guangzhou 510632, ChinaDepartment of Radiology, The First Affiliated Hospital of Jinan University, Guangzhou 510632, ChinaSelenium nanoparticle (SeNP)-based nanotherapeutics have become an emerging cancer therapy, while effective drug delivery remains a technical hurdle. A theranostic approach, through which imaging companions are integrated with SeNPs, will allow image-guided drug delivery and, therefore, is highly desirable. Traditional methods require the chemical conjugation of imaging agents to the surface of nanoparticles, which may impede the later clinical translation. In this study, we developed a label-free strategy in which lentinan-functionalized SeNPs (LNT-SeNPs) are detected using MRI by the hydroxyl protons carried on LNT molecules. The in vitro phantom study showed that LNT and LNT-SeNPs have a strong CEST signal at 1.0 ppm apart from the water resonance, suggesting an in vivo detectability in the µM concentration range. Demonstrated on CT26 colon tumor cells, LNT-SeNPs exert a strong anticancer effect (IC50 = 4.8 μM), prominently attributed to the ability to generate intracellular reactive oxygen species. However, when testing in a mouse model of CT26 tumors, administration of LNT-SeNPs alone was found unable to deliver sufficient drugs to the tumor, leading to poor treatment responses. To improve the drug delivery, we co-injected LNT-SeNPs and TNF-α, a previously reported drug that could effectively damage the endothelial cells in the tumor vasculature, thereby increasing drug delivery to the tumor. Our results revealed a 75% increase in the intratumoral CEST MRI signal, indicating a markedly increased delivery efficiency of LNT-SeNPs when combined with TNF-α. The combination therapy also resulted in a significantly enhanced treatment outcome, as revealed by the tumor growth study. Taken together, our study demonstrates the first label-free, SeNP-based theranostic system, in which LNT was used for both functional surface coating and CEST MRI signal generating. Such a theranostic LNT-SeNP system is advantageous because it requires chemical labeling and, therefore, has high biocompatibility and low translatable barriers.https://www.mdpi.com/1999-4923/15/1/120nanotherapeuticsselenium nanoparticleslentinanMRI
spellingShingle Guanfu Liu
Jiabao Ling
Lizhen He
Yuan Xu
Tianfeng Chen
Changzheng Shi
Liangping Luo
Theranostic Cancer Treatment Using Lentinan-Coated Selenium Nanoparticles and Label-Free CEST MRI
Pharmaceutics
nanotherapeutics
selenium nanoparticles
lentinan
MRI
title Theranostic Cancer Treatment Using Lentinan-Coated Selenium Nanoparticles and Label-Free CEST MRI
title_full Theranostic Cancer Treatment Using Lentinan-Coated Selenium Nanoparticles and Label-Free CEST MRI
title_fullStr Theranostic Cancer Treatment Using Lentinan-Coated Selenium Nanoparticles and Label-Free CEST MRI
title_full_unstemmed Theranostic Cancer Treatment Using Lentinan-Coated Selenium Nanoparticles and Label-Free CEST MRI
title_short Theranostic Cancer Treatment Using Lentinan-Coated Selenium Nanoparticles and Label-Free CEST MRI
title_sort theranostic cancer treatment using lentinan coated selenium nanoparticles and label free cest mri
topic nanotherapeutics
selenium nanoparticles
lentinan
MRI
url https://www.mdpi.com/1999-4923/15/1/120
work_keys_str_mv AT guanfuliu theranosticcancertreatmentusinglentinancoatedseleniumnanoparticlesandlabelfreecestmri
AT jiabaoling theranosticcancertreatmentusinglentinancoatedseleniumnanoparticlesandlabelfreecestmri
AT lizhenhe theranosticcancertreatmentusinglentinancoatedseleniumnanoparticlesandlabelfreecestmri
AT yuanxu theranosticcancertreatmentusinglentinancoatedseleniumnanoparticlesandlabelfreecestmri
AT tianfengchen theranosticcancertreatmentusinglentinancoatedseleniumnanoparticlesandlabelfreecestmri
AT changzhengshi theranosticcancertreatmentusinglentinancoatedseleniumnanoparticlesandlabelfreecestmri
AT liangpingluo theranosticcancertreatmentusinglentinancoatedseleniumnanoparticlesandlabelfreecestmri